Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Ford

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Alimentary Pharmacology & Therapeutics|March 23, 2017
Letter: NICE referral criteria for lower gastrointestinal alarm features - not ideal but not poor either. Authors' replyS J Simpkins, M I Pintos-Sanchez, P Moayyedi, et al.
Inflammatory Bowel Diseases|October 11, 2007
Mycophenolate mofetil therapy for refractory inflammatory bowel diseaseS Palaniappan, A C Ford, D Greer, et al.
Gut|August 5, 2008
Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysisA C Ford, S J O Veldhuyzen van Zanten, C C Rodgers, et al.
The Journal of Biological Chemistry|October 27, 1995
Stable inducible expression of a functional rat liver organic anion transport protein in HeLa cellsX Shi, S Bai, A C Ford, et al.
Gut|December 19, 2008
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic reviewP Moayyedi, A C Ford, N J Talley, et al.
Alimentary Pharmacology & Therapeutics|April 17, 2026
The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical RelevanceT E Conley, A Duncan, A Modasia, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2017
Editorial: latent class analysis to improve confidence in the diagnosis of IBS - authors' replyR Sood, D J Gracie, M J Gold, et al.
Alimentary Pharmacology & Therapeutics|January 21, 2017
Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysisR Sood, D J Gracie, M J Gold, et al.
Alimentary Pharmacology & Therapeutics|November 6, 2010
Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experienceM B Sprakes, A C Ford, N C Suares, et al.
Alimentary Pharmacology & Therapeutics|October 26, 2016
The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel diseaseC P Selinger, I Carbery, V Warren, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Alimentary Pharmacology & Therapeutics|March 23, 2017
Letter: NICE referral criteria for lower gastrointestinal alarm features - not ideal but not poor either. Authors' replyS J Simpkins, M I Pintos-Sanchez, P Moayyedi, et al.
Inflammatory Bowel Diseases|October 11, 2007
Mycophenolate mofetil therapy for refractory inflammatory bowel diseaseS Palaniappan, A C Ford, D Greer, et al.
Gut|August 5, 2008
Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysisA C Ford, S J O Veldhuyzen van Zanten, C C Rodgers, et al.
The Journal of Biological Chemistry|October 27, 1995
Stable inducible expression of a functional rat liver organic anion transport protein in HeLa cellsX Shi, S Bai, A C Ford, et al.
Gut|December 19, 2008
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic reviewP Moayyedi, A C Ford, N J Talley, et al.
Alimentary Pharmacology & Therapeutics|April 17, 2026
The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical RelevanceT E Conley, A Duncan, A Modasia, et al.
Alimentary Pharmacology & Therapeutics|April 4, 2017
Editorial: latent class analysis to improve confidence in the diagnosis of IBS - authors' replyR Sood, D J Gracie, M J Gold, et al.
Alimentary Pharmacology & Therapeutics|January 21, 2017
Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysisR Sood, D J Gracie, M J Gold, et al.
Alimentary Pharmacology & Therapeutics|November 6, 2010
Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experienceM B Sprakes, A C Ford, N C Suares, et al.
Alimentary Pharmacology & Therapeutics|October 26, 2016
The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel diseaseC P Selinger, I Carbery, V Warren, et al.
Pageof 10